Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Biotechnology
- Veterinary
- Agriculture
- Forestry and Fishing
- Technical Know How
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5336
License Grant
The Scottish Institute grants subject as provided below, the exclusive right and licence, with a right to sublicense, under the Institute's Patents to research, develop, manufacture, and/or Supply the Products and/or Services and to commercializes, exploit, market, import and export and sell the Products and/or Services in the Field anywhere in the Territory.
License Property
Patent Mariner (use of Mariner in the production of Transgenic Animals) and 5,011,780- Avian embryos may be cultured in vitro up to blastoderm formation, during embryonic morphogenesis and/or during embryonic growth to hatch. The invention may have applications not only in the genetic engineering of poultry, but also in the investigation of fundamental mechanisms of avian development and in the study of deleterious traits. Moreover, it may afford a desirable alternative to surgical intervention in the laying hen.
Field of Use
Field means therapeutic and diagnostic protein production in avian species.
IPSCIO Record ID: 256191
License Grant
The University grants the sole and exclusive right and license to make, use, offer to sell, sell, import and sublicense Licensed Patents within the Field of Use and in the Licensed Territory for the Term.
License Property
The patents include, but are not limited to
— Production of Transgenic Early Embryonic Chicken Cells and Chimeric Chickens Using EGFP and Puromycin Selection Methods,
— Transgenesis of Early Embryonic Cells,
— Avians that Produce Eggs Containing Exogenous Proteins,
— Exogenous Proteins Expressed in Avians and Their Eggs,
— Novel Vectors in Avian Transgenesis,
— Vectors Comprising a Magnum-Specific Promoter for Avian Transgenesis, and,
— Method for Manipulating Eggs
Field of Use
The Field of Use means avian trans genesis as it may relate to introduction of DNA sequences in any avian species expression of autologous and allogeneic molecules in any avian species, use of avians and their eggs as bioreactor] and improved poultry production genetics.
IPSCIO Record ID: 26235
License Grant
The parties entered into a development, licence and collaboration agreement to collaborate in a research and development project in the field of therapeutic and diagnostic protein production in avian species.
Field of Use
Field means therapeutic and diagnostic protein production in avian species.
IPSCIO Record ID: 28404
License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof a) A royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services.
By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licensee’s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licensee’s exclusive rights shall revert to nonexclusive rights.
License Property
“Act Animal Cell Lines†shall mean cell lines of non-human animal origin developed by Act. These cell lines shall include but not be limited to murine and primate embryonic stem cells derived through parthenogenesis, nuclear transfer or otherwise isolated from fertilized blastocysts including the relevant information Licensor possesses associated with these cells, including but not limited to information on the cell’s karyotype, gene expression and growth characteristics.
PATENT RIGHTS
08/935,052 US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos
6,235,970 2001-05-22 Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS
10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.
b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.
Potential patent interferences, verbally threatened to be filed against the following patents
a) 6,215,041
b) 6,235,969
Field of Use
“Field†shall mean (1) the research, development, manufacture and selling of human and non-human animal cells and Act Animal Cell Lines for commercial research use, including small molecule and other drug testing and basic research, (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases, and (3) the use of Act Animal Cell Lines in the process of manufacturing and selling human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases but where the final marketed product does not include Act Animal Cell Lines (i.e. does not include the field of xenotransplantation); but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
